CONCLUSION: Electrochemotherapy (ECT) is an efficacious treatment. It should, however, be used with some caution in the treatment of head and neck cancer. OBJECTIVES: To assess local tumor control, safety, survival, and functional outcome after treatment of cancer in the head and neck region with ECT. METHODS: Four patients with primary T2 cancer of the oral cavity or oropharynx and one patient with a metastasis of renal cancer in the masseter muscle were treated with ECT with intratumorally administered bleomycin. Control biopsies were carried out 2 months after treatment. Postoperative radiotherapy was performed based on tumor T-stage and the depth of tumor infiltration. Serious adverse events and treatment malfunctions were recorded. The follow-up time was 24 months for the surviving patients and 20 months overall. The PSS-HN scale was used to assess the functional outcome. RESULTS: No local recurrence was recorded in any patient during the follow-up. However, only one patient was treated with ECT alone. There were four serious adverse events: one nearly lethal bleeding, two cases of osteoradionecrosis, and a fistula. One patient died from distant metastasis. The other patients were tumor-free both locally and overall at 24 months. The median functional outcome in all parameters was worse 1 year after treatment.
CONCLUSION: Electrochemotherapy (ECT) is an efficacious treatment. It should, however, be used with some caution in the treatment of head and neck cancer. OBJECTIVES: To assess local tumor control, safety, survival, and functional outcome after treatment of cancer in the head and neck region with ECT. METHODS: Four patients with primary T2 cancer of the oral cavity or oropharynx and one patient with a metastasis of renal cancer in the masseter muscle were treated with ECT with intratumorally administered bleomycin. Control biopsies were carried out 2 months after treatment. Postoperative radiotherapy was performed based on tumor T-stage and the depth of tumor infiltration. Serious adverse events and treatment malfunctions were recorded. The follow-up time was 24 months for the surviving patients and 20 months overall. The PSS-HN scale was used to assess the functional outcome. RESULTS: No local recurrence was recorded in any patient during the follow-up. However, only one patient was treated with ECT alone. There were four serious adverse events: one nearly lethal bleeding, two cases of osteoradionecrosis, and a fistula. One patient died from distant metastasis. The other patients were tumor-free both locally and overall at 24 months. The median functional outcome in all parameters was worse 1 year after treatment.
Entities:
Keywords:
Electroporation therapy; bleomycin; head and neck cancer; local control; serious adverse events; survival
Authors: Armando De Virgilio; Massimo Ralli; Lucia Longo; Patrizia Mancini; Giuseppe Attanasio; Francesca Atturo; Marco De Vincentiis; Antonio Greco Journal: Oncol Lett Date: 2018-07-12 Impact factor: 2.967
Authors: Gianluca Di Monta; Corrado Caracò; Ester Simeone; Antonio Maria Grimaldi; Ugo Marone; Massimiliano Di Marzo; Vito Vanella; Lucia Festino; Marco Palla; Stefano Mori; Nicola Mozzillo; Paolo Antonio Ascierto Journal: J Transl Med Date: 2017-04-26 Impact factor: 5.531
Authors: Mahammad M Davudov; Iraj Harirchi; Ali Arabkheradmand; Ata Garajei; Habibollah Mahmudzadeh; Mohammad Shirkhoda; Maziar Motiee-Langroudi; Zoheir Mirzajani; Jayran Zebardast; Ali Montazeri Journal: Medicine (Baltimore) Date: 2019-10 Impact factor: 1.817
Authors: Primož Strojan; Aleš Grošelj; Gregor Serša; Christina Caroline Plaschke; Jan B Vermorken; Sandra Nuyts; Remco de Bree; Avraham Eisbruch; William M Mendenhall; Robert Smee; Alfio Ferlito Journal: Cancers (Basel) Date: 2021-03-12 Impact factor: 6.639